Skip to main content
ANIK
NASDAQ Industrial Applications And Services

Anika 10-Q: Q3 Revenue $30.6M; FDA Deems Hyalofast PMA Not Approvable

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$14.62
Mkt Cap
$195.659M
52W Low
$9.01
52W High
$22.88
52W Position info
62% above low
Off High info
36% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ANIK sits 62% above its 52-week low of $9.01.

Summary

Anika's Q3 revenue rose 10% to $30.6 million and the net loss narrowed to $0.3 million, but the 10-Q discloses that the FDA deemed its Hyalofast PMA application not approvable in October 2026, leaving Cingal's NDA as the main U.S. regulatory catalyst.


Key Events · Earnings and Guidance · ANIK

  • Q3 Revenue Up 10% to $30.6M

    Revenue rose to $30,594 thousand from $27,817 thousand, with Commercial Channel revenue up 17% to $13,993 thousand and OEM Channel up 5% to $16,601 thousand.

  • Net Loss Narrowed to $0.3M

    Q3 loss from continuing operations was $311 thousand versus $3,175 thousand a year earlier; nine-month adjusted EBITDA was $16,478 thousand versus $804 thousand.

  • FDA: Hyalofast PMA Not Approvable

    In October 2026 the FDA formally notified Anika that its Hyalofast PMA application is not approvable, primarily based on the clinical data submitted; the company will continue discussions on evidence needed for future approval.

  • Cash Down to $45.0M on Inventory Build

    Cash and equivalents fell to $44,957 thousand from $57,481 thousand at December 31, 2025, as inventories rose $14,327 thousand; nine-month operating cash flow was $2,847 thousand versus $6,551 thousand.


Analysis · ANIK · Industrial Applications And Services

The quarter was solid on its own: revenue rose 10% to $30.6 million, gross margin reached 62% versus 56%, and the net loss narrowed to $0.3 million from $3.2 million. The more consequential news sits deeper in the filing. In October 2026 the FDA told Anika that its Hyalofast PMA application is not approvable on the clinical data submitted, removing the nearest-term U.S. approval path for the cartilage repair product and shifting the growth story onto Cingal, whose NDA is now targeted for December 31, 2027. Cash fell to $45.0 million from $57.5 million at year-end as inventories built by $14.3 million ahead of demand, though a $50 million undrawn revolver and $2.8 million of nine-month operating cash flow keep the balance sheet comfortable. Partly offsetting the Hyalofast setback is a November 5 extension of a non-orthopedic distribution deal through 2036, worth $8.0 million including a $4.0 million upfront payment in Q1 2027.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANIK was trading at $14.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $195.7M. The 52-week trading range was $9.01 to $22.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANIK - Latest Insights

ANIK
Nov 06, 2026, 7:06 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $18.81
Real-time Price: $14.45 info
Change: -$4.36 (-23%) info
Market Cap: $193.384M info
ANIK
Nov 06, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.81
Real-time Price: $14.45 info
Change: -$4.36 (-23%) info
Market Cap: $193.384M info
ANIK
Jul 29, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.49
Real-time Price: $14.45 info
Change: -$2.04 (-12%) info
Market Cap: $193.384M info
ANIK
Jul 29, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.50
Real-time Price: $14.45 info
Change: -$1.05 (-7%) info
Market Cap: $193.384M info
ANIK
Jun 23, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.59
Real-time Price: $14.45 info
Change: -$0.140 (-0.96%) info
Market Cap: $193.384M info